Sight SciencesSGHT Market cap $292M
About: Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Employees: 214
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
114% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 14
65% more call options, than puts
Call options by funds: $205K | Put options by funds: $124K
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
27% more capital invested
Capital invested by funds: $88.4M [Q1] → $112M (+$23.8M) [Q2]
8% more funds holding
Funds holding: 65 [Q1] → 70 (+5) [Q2]
0.07% more ownership
Funds ownership: 33.75% [Q1] → 33.82% (+0.07%) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Lake Street Frank Takkinen 53% 1-year accuracy 8 / 15 met price target | 72%upside $10 | Buy Initiated | 21 Aug 2024 |
Morgan Stanley Cecilia Furlong 57% 1-year accuracy 4 / 7 met price target | 12%upside $6.50 | Equal-Weight Maintained | 15 Jul 2024 |
Citigroup Joanne Wuensch 79% 1-year accuracy 19 / 24 met price target | 12%upside $6.50 | Neutral Maintained | 10 Jul 2024 |